Adalimumab biosimilars have similar disease relapse rates to originator adalimumab when treating non-infectious uveitis
Accept poster if oral is not possible ?
No
Purpose
To compare the efficacy in achieving and maintaining control of inflammation between adalimumab biosimilars and originator adalimumab, as initial biologic treatment among adult patients with refractory non-infectious uveitis (NIU).
Methods
A multi-center retrospective cohort study of 260 eyes of 148 patients diagnosed with NIU who received initial biologic treatment of either originator adalimumab or a biosimilar. Events of uveitis relapse were noted per-eye following initiation of adalimumab treatment. Relapse rates and time to first relapse by 12 months, were compared between eyes treated with originator adalimumab or a biosimilar.
Results
Eyes were treated with either originator adalimumab (n=193, 74.23%) or a biosimilar (n=67, 25.77%). Median follow-up from baseline for patients who did not relapse was 24.0 [IQR 18.0, 24.0]. Uveitis relapses occurred in 97 eyes (37.31%, 76 in the adalimumab group and 21 in the biosimilar group). By twelve months, the estimated relapse rate was 24.2% in the adalimumab group vs. 28.3% in the biosimilar group (Relative risk=1.17, 95% CI 0.58 to 1.77). The average time to relapse by 12 months follow-up for the adalimumab group was 4.91 months compared with 5.04 months in the biosimilars group (mean difference 0.13 months, 95% CI -1.33 1.54 months).
Conclusion
Our study suggest that by twelve months use, biosimilar adalimumab agents were not inferior to originator adalimumab in preventing disease relapse among patients with refractory NIU. These results support the use of biosimilar adalimumab for treating NIU.
Conflict of interest
No
1
Last name
TOMKINS-NETZER
Initials of first name(s)
O
Department
Department of Ophthalmology, Lady Davis Carmel Medical Center
City
Haifa
Country
Israel
2
Last name
Sharon
Initials of first name(s)
Y
Department
Department of Ophthalmology, Rabin Medical Center
City
Petach Tikva
Country
Israel
3
Last name
Niederer
Initials of first name(s)
R
Department
Department of Ophthalmology, Auckland District Health Board
City
Auckland
Country
New Zealand
4
Last name
Amar
Initials of first name(s)
R
Department
Department of Ophthalmology, Hadassah Medical Center
City
Jerusalem
Country
Israel
5
Last name
Sar
Initials of first name(s)
S
Department
Department of Ophthalmology, Lady Davis Carmel Medical Center
City
Haifa
Country
Israel
6
Last name
Habot-Wilner
Initials of first name(s)
Z
Department
Division of Ophthalmology, Tel Aviv Sourasky Medical Center
City
Tel Aviv
Country
Israel
7
Last name
Gepstein
Initials of first name(s)
R
Department
Department of Ophthalmology, Meir Medical Center
City
Kfar Sava
Country
Israel
8
Last name
Shyriaieva
Initials of first name(s)
H
Department
Department of Ophthalmology, Emek Medical Center
City
Afula
Country
Israel
9
Last name
Diab
Initials of first name(s)
R
Department
Department of Ophthalmology, Lady Davis Carmel Medical Center
City
Haifa
Country
Israel
10
Last name
Corredores
Initials of first name(s)
J
Department
Department of Ophthalmology, Hadassah Medical Center
City
Jerusalem
Country
Israel
11
Last name
Cohen
Initials of first name(s)
S
Department
Division of Ophthalmology, Tel Aviv Sourasky Medical Center
City
Tel Aviv
Country
Israel
12
Last name
Barnett-Griness
Initials of first name(s)
O
Department
Department of Community Medicine and Epidemiology, Lady Davis Carmel Medical Center
City
Haifa
Country
Israel
13
Last name
Kramer
Initials of first name(s)
M
Department
Department of Ophthalmology, Rabin Medical Center
City
Petach Tikva
Country
Israel
This website uses cookies to ensure you get the best experience on our website.
Learn more